Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Genetically Modified Immune Cells Targeting Tumor Antigens Publisher Pubmed



Poorebrahim M1 ; Abazari MF2 ; Sadeghi S3 ; Mahmoudi R4 ; Kheirollahi A5 ; Askari H6 ; Wickstrom SL1 ; Poortahmasebi V7, 8, 9 ; Lundqvist A1 ; Kiessling R1 ; Cidarregui A10
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
  2. 2. Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Medical Biotechnology, Tabriz University of Medical Sciences, Tabriz, Iran
  5. 5. Department of Comparative Biosciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
  6. 6. Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  7. 7. Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  8. 8. Infectious and Tropical Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  9. 9. Faculty of Medicine, Department of Bacteriology and Virology, Tabriz University of Medical Sciences, Tabriz, Iran
  10. 10. Targeted Tumor Vaccines Group, Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany

Source: Pharmacology and Therapeutics Published:2020


Abstract

Immunotherapy approaches consisting of genetically modified immune cells have become a promising platform for cancer treatment. Such ‘living’ therapies targeting tumor antigens have shown success in many cancer patients in the form of durable responses in a growing number of clinical studies. Besides, a large number of ongoing studies have been designed to introduce reliable methods for identification of tumor antigens. In addition, technical and biotechnological developments are being applied to the generation and expansion of genetically modified immune cells. In this review, we summarize and discuss the latest progress and current challenges in the tumor antigen landscape and in the generation of genetically modified immune cells in view of their clinical efficacy, either as monotherapy or combinational therapy. © 2020 Elsevier Inc.
Experts (# of related papers)
Other Related Docs
9. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)
12. Car-Nk Cells: A Promising Cellular Immunotherapy in Lymphoma, Expert Opinion on Biological Therapy (2023)
15. Car-Nk Cell: A New Paradigm in Tumor Immunotherapy, Frontiers in Oncology (2021)
26. Immunotherapy in Aml: A Brief Review on Emerging Strategies, Clinical and Translational Oncology (2021)
27. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
30. Car-Modified T-Cell Therapy for Cancer: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
37. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
38. Immunotherapy for Breast Cancer Treatment, Iranian Biomedical Journal (2021)
39. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
45. Chimeric Antigen Receptor T-Cell Therapy for Melanoma, Expert Review of Clinical Immunology (2021)
46. Crispr/Cas9 Revitalizes Adoptive T-Cell Therapy for Cancer Immunotherapy, Journal of Experimental and Clinical Cancer Research (2021)
47. Tumor Antigens, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
49. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)